Q4 2025 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a total revenue of $534 million for 2025, reflecting a 15% growth over 2024.
- The company achieved nearly $62 million in adjusted EBITDA and generated $45 million in cash in 2025.
- AtriCure Inc (ATRC) launched two new products in 2025, the AtriClip PRO Mini and cryoXT PRO, contributing to revenue growth.
- The LeAAPS clinical trial completed enrollment of over 6,500 patients, ahead of expectations, showcasing strong interest and participation.
- The EnCompass Clamp has been a significant growth driver, with over 830 accounts worldwide and a mid-teens increase over 2024.
- The UK market faced a decline in sales due to ongoing funding and reimbursement uncertainty with the National Health Service.
- The minimally invasive Afib treatment segment saw a 26% decline in revenue for 2025, pressured by PFA adoption in the US.
- The hybrid Afib therapy segment experienced a strong headwind throughout 2025, with a $16 million total decline in US MIS ablation and MIS appendage management devices.
- The company anticipates continued pressure in the US hybrid business in 2026, although at a moderated rate compared to 2025.
- International revenue growth was impacted by a decline in sales in the UK, which was previously the fastest-growing European market for AtriCure Inc (ATRC).
Good afternoon, and welcome to AtriCure's fourth-quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Great. Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644-4484 to have one e-mailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings.
These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
